A recent meta-analysis including 7 trials evaluating anti PD-1 in advanced SCC with a subgroup analysis of the odds ratio for ORR by PD-L1 tumor proportion score found an OR of 2.81 for ORR in patients with a PD-L1 tumor proportion score of ≥1% [31,34,36,37]. Here, CD274 is linked to neoplasm.